X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
R-107 is a liquid, nitric oxide-releasing compound with issued and pending composition of matter and method of use patents in approximately 40 countries, including the U.S., Australia, Brazil, China, Europe, India, Japan, Russia and South Korea.
Lead Product(s): Nitric oxide-releasing compound
Therapeutic Area: Cardiology/Vascular Diseases Product Name: R-107
Highest Development Status: PreclinicalProduct Type: Small molecule
Recipient: CMAX
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Agreement April 21, 2021
Details:
Claritas is currently developing R-107 for the treatment of viral infections, including vaccine-resistant COVID-19. Claritas will also now expand this program to include development of R-107 for the treatment of COVID-19 related sepsis.
Lead Product(s): Nitric oxide releasing compound
Therapeutic Area: Infections and Infectious Diseases Product Name: R-107
Highest Development Status: PreclinicalProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 08, 2021
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
